National Comprehensive Cancer Network Oncology Research Program 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.NCCN Receives $2.1 Million in Oncology Research Funding from Pfizer
NCCN recently received a $2.1 million research grant from Pfizer to gain further insights into the use of the investigational compound Axitinib in various tumor types. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
November 30, 2010
FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) has been awarded a $2.1 million grant from Pfizer to develop a program to scientifically evaluate and define the clin... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 30, 2010 Category: Cancer & Oncology Source Type: news
NCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline
NCCN recently received two individual $2 million research grants from GlaxoSmithKline to evaluate the effectiveness of ofatumumab in hematologic malignancies and pazopanib in the treatment of solid tumors. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
July 27, 2010
FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN) has been awarded two individual $2 million grants from GlaxoSmithKline (GSK) to support clinical stud... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - July 27, 2010 Category: Cancer & Oncology Source Type: news
NCCN Survey Analyzes Clinical Trial Accrual at Academic Cancer Centers
Identifying clinical trial benchmarking metrics and best practices at NCCN Member Institutions is the focus of a recent survey conducted by the National Comprehensive Cancer Network® (NCCN®). A poster presentation of the survey analysis will be featured at the 2010 ASCO Annual Meeting on June 7, 2010.
June 4, 2010
FORT WASHINGTON — Clinical research is at the heart of National Comprehensive Cancer Network® (NCCN®) center operations, as it constitut... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - June 4, 2010 Category: Cancer & Oncology Source Type: news
NCCN Receives Research Grant to Evaluate Pralatrexate in Solid Tumors and Hematologic Malignancies
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
November 10, 2009
FORT WASHINGTON, PA — The National Comprehensive Cancer Networ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 10, 2009 Category: Cancer & Oncology Source Type: news
NCCN Holds Oncology Research Best Practices Conference
NCCN is holding the NCCN Oncology Research Best Practices Conference™, an interactive forum to discuss the regulatory and operational aspects of research and help identify areas in the clinical trial process where improvements can be made. Scheduled for October 26 – 27 in Bethesda, MD, the conference will include lectures, interactive workshops, and panel discussions on topics that challenge the conduct of oncology research as well as topics related to ethical consideration... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 14, 2009 Category: Cancer & Oncology Source Type: news
NCCN Oncology Research Program Celebrates 10th Anniversary by Closing in on $20 Million in Funding; Program Expands into Developmental Therapies
The NCCN Oncology Research Program (ORP) nears the $20 million mark in total funding and enhances its current model to include funding for therapeutics in development as well as those already FDA-approved. The ORP draws on the expertise of investigators at 21 of the world’s leading cancer centers (NCCN Member Institutions) in order to advance therapeutic options for patients with cancer.
April 29, 2009
FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCC... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - April 29, 2009 Category: Cancer & Oncology Source Type: news
NCCN Receives $4 Million Oncology Research Grant from Wyeth
NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC). This grant is the largest research award received by NCCN to date. Investigators from NCCN Member Institutions are eligible to apply for the research funding.
January 15, 2009
FORT WASHINGTON, PA — The National Comprehensive Cancer Networ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - January 15, 2009 Category: Cancer & Oncology Source Type: news
Combination Cancer Therapy is Focus of $1M Merck Research Grant Received by NCCN
NCCN has been awarded a $1M research grant from Merck & Co, Inc., that will support research of the anti-cancer agent vorinostat (Zolinza®). Vorinostat is currently used to treat progressive, persistent, or recurrent cutaneous T-cell lymphoma. This research grant will fund studies to explore the efficacy of vorinostat in combination with chemotherapy and/or radiation therapy in selected locally advanced non-metastatic cancers including non-small cell lung cancer, head and neck cancer, panc... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - December 1, 2008 Category: Cancer & Oncology Source Type: news
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
NCCN has been awarded a $1.5 Million grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated to fund research on the antibody cetuximab in patients with bladder cancer. The novel targeted therapy has proven effective in various other types of cancer including colorectal and head and neck. The University of Michigan Comprehensive Cancer Center is the coordinating center for the study.
November 24, 2008
FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 24, 2008 Category: Cancer & Oncology Source Type: news
NCCN Receives Major Grant for Anti-Cancer Drug Study
JENKINTOWN, Pa., November 15, 2007 — The National Comprehensive Cancer Network (NCCN), ImClone Systems Incorporated and Bristol-Myers Squibb have entered into a collaboration to conduct a multi-institutional, investigator-initiated study in head and neck cancer using cetuximab. Fox Chase Cancer Center (FCCC) in Philadelphia, Pennsylvania is the coordinating center for this study, with Corey Langer, M.D., serving as Project Chairman.
Cetuximab, also known by its brand name ERBITUX®, is current... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 15, 2007 Category: Cancer & Oncology Source Type: news
NCCN Receives $2 Million Grant from Pfizer
Funding will support innovative cancer research JENKINTOWN, Pa., September 5, 2006 — The National Comprehensive Cancer Network (NCCN) and Pfizer, Inc., have entered into a collaboration to conduct research on the oral multikinase inhibitor sunitinib (Sutent), a drug currently approved for advanced renal cell carcinoma and gastrointestinal stromal tumors. Sutent is being studied in a broad range of solid tumors. “NCCN’s goal is to improve the quality, effectiveness and efficiency of oncology prac... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - September 5, 2006 Category: Cancer & Oncology Source Type: news
NCCN and Roche Collaborate on Innovative Cancer Research
JENKINTOWN, Pa., October 31, 2005 — The National Comprehensive Cancer Network (NCCN) announced that it has entered into a collaboration with Roche Laboratories, Inc. to develop and review ongoing oncology research protocols and trials examining Xeloda® (capecitabine) in combination with radiologic therapy, and other drugs and biologics in the treatment of solid tumors including esophageal, gastric and pancreatic cancers.
“NCCN’s mission is to improve cancer care by studying and evaluating new ... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - October 31, 2005 Category: Cancer & Oncology Source Type: news
Diane E. Paul, MS, RN, Joins National Comprehensive Cancer Network as Vice President, Clinical Trials Network
JENKINTOWN, Pa., June 13, 2005 — William T. McGivney, Ph.D., CEO of the National Comprehensive Cancer Network (NCCN), announces that Diane E. Paul, MS, RN, has joined NCCN as Vice President, Clinical Trials Network. In this role, Paul will be responsible for developing a centralized, standardized infrastructure for the conduct of clinical trials among NCCN’s 19 member institutions.
“This network will be of interest to pharmaceutical/biotechnology companies for the conduct of their trials. And... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - June 13, 2005 Category: Cancer & Oncology Source Type: news
Researchers Receive $1,886,237 in Funding from NCCN Clinical Trials Network
ROCKLEDGE, PA, February 20, 2003 - The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, is very pleased to announce the awarding of $1,886,237 in research grants provided through the NCCN Clinical Trials Network (CTN).
“NCCN’s Clinical Trials Network, a program devoted to facilitating the development of promising new therapeutics to improve patient outcomes, is very pleased to offer research funding to support investigator-initiated... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - February 20, 2003 Category: Cancer & Oncology Source Type: news
The National Comprehensive Cancer Network Provides Physicians Easier Identification of Clinical Trials for Their Patients
ROCKLEDGE, PA, November 5, 2002 – The National Comprehensive Cancer Network (NCCN) today announced changes made to their Web site (www.nccn.org) which will allow physicians to more easily locate clinical trials. Physicians seeking new treatments for their patients with cancer often turn to clinical trials for answers. These research studies include trials testing new treatments, such as a new cancer drug or a new combination of drugs, new approaches to surgery or radiation therapy, or new ther... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - November 5, 2002 Category: Cancer & Oncology Source Type: news
